Previous Close | 15.85 |
Open | 15.96 |
Bid | 14.92 x 800 |
Ask | 14.96 x 1600 |
Day's Range | 14.74 - 16.89 |
52 Week Range | 3.53 - 23.86 |
Volume | |
Avg. Volume | 16,843,983 |
Market Cap | 2.204B |
Beta (5Y Monthly) | 1.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.05 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.80 |
Here is how Boston Scientific (BSX) and Novavax (NVAX) have performed compared to their sector so far this year.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
The average brokerage recommendation (ABR) for Novavax (NVAX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?